Logotipo del SMU


Uruguayan Medical Journal

ISSN: 1688-0390

Vol.17 - Nº 1 - Abr. 2001

Previous Art | Index | Next Art

Hormonal therapy in prostate cancer. Clinical pharmacology

Rev Med Urug 2001; 17: 10-16
Full text (spanish) |  Full text (spanish) (New windows, pdf) | Abstract


Diverse pharmacological strategies are currently used to suppress testosterone at castration levels in the management of prostate cancer. For the last 15 years, risk/benefit and cost/benefit relationships of many hormonal action products over this pathology have been changed. Historically, synthetic oestrogen have been playing an important role in the course of hormonal therapy against prostate cancer. Despite its high cost-effectiveness compared to modern products, they have been relegated because of the controversial cardiotoxicity observed using high dosage. LHRH superagonist have had big success in treatment approaches, particularly the depot parenteral dosage; however, more attention should be drawn on cost effectiveness. Steroidal and non-steroidal antiandrogen contribute to total androgenic blockage. Since they work differently and produce diverse degrees of impact over plasmatic hormones, they express different risk/benefit values. To determine combined therapy in cancer of prostate, pharmacokinetics and pharmacodynamics of antiandrogen must be known because they may interact with LHRH superagonist.